Radnostix Signs Definitive Agreement to Divest DUF6 and Fluorine Assets to NANO Nuclear
Transaction Terms and Next Steps
The proposed acquisition would provide NANO Nuclear with existing NRC 10 CFR Part 40 licensed fuel cycle assets and a substantial body of associated licensing and technical work. The NRC license was originally issued in connection with a proposed facility in
Under the asset purchase agreement, the consideration being paid for the assets at closing is
Radnostix Focus on Radioisotope Technologies
This transaction represents a major centering event for Radnostix, allowing the Company to focus on its core radioisotope technology segments while significantly strengthening its balance sheet for the next chapter of the business. Following closing, Radnostix intends to utilize the net proceeds to accelerate the growth of its four radioisotope technology product segments through a combination of enhanced research and development and continued organic and inorganic growth initiatives.
"We have complete confidence in NANO to take these DUF6 deconversion and fluorine extraction assets across the finish line and fill a material need for the
About Radnostix (formerly International Isotopes Inc.): Radnostix, Inc. (formerly International Isotopes Inc.) (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope technology products. Radnostix manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer, the contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. Radnostix also manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. For more information, visit www.radnostix.com.
Radnostix, Inc. (formerly International Isotopes Inc.) Safe Harbor Statement:
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to, statements regarding the Company's current expected financial impact from the Asset Purchase Agreement described herein, the estimated value of the DUF6 Plant and related assets, statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of Radnostix, Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2025. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and Radnostix, Inc. and the Company undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Radnostix Contact:
[email protected]
radnostix.com
View original content:https://www.prnewswire.com/news-releases/radnostix-signs-definitive-agreement-to-divest-duf6-and-fluorine-assets-to-nano-nuclear-302895541.html
SOURCE International Isotopes Inc.

